Mahmoud Omar | Drug Delivery Using Nanotechnology | Excellence in Innovation Award

Published on by Global Nano Awards

Prof. Dr. Mahmoud Omar | Drug Delivery Using Nanotechnology | Excellence in Innovation Award

Deraya University | Egypt

Prof. Dr. Mahmoud Omar, Associate Professor of Pharmaceutics at Deraya University, Egypt, is a leading expert in pharmaceutics and pharmaceutical nanotechnology, with a primary focus on advanced drug delivery systems and nanomedicine. His prolific research portfolio demonstrates a strong commitment to innovation in pharmaceutical sciences. His distinguished studies include Nanomedicine Fight against Antibacterial Resistance: An Overview of the Recent Pharmaceutical Innovations, Preparation and Optimization of Lidocaine Transferosomal Gel Containing Permeation Enhancers: A Promising Approach for Enhancement of Skin Permeation, Nanogel Loaded with Surfactant-Based Nanovesicles for Enhanced Ocular Delivery of Acetazolamide, Nanostructured Lipid Carriers to Mediate Brain Delivery of Temazepam: Design and In Vivo Study, and A Universal Suspension Test Rig for Electrohydraulic Active and Passive Automotive Suspension System. He has also contributed significantly through works such as Synthesis of Ultrastable Gold Nanoparticles as a New Drug Delivery System, Pathogenesis of Staphylococcus Haemolyticus on Primary Human Skin Fibroblast Cells, Liposomal Flucytosine Capped with Gold Nanoparticles Formulations for Improved Ocular Delivery, and Targeting Brain Cells with Glutathione-Modulated Nanoliposomes: In Vitro and In Vivo Study. Further, his research includes Sesame Oil-Based Nanostructured Lipid Carriers of Nicergoline for Intranasal Brain Targeting, Evaluation of Serum Cystatin C as a Marker of Early Renal Impairment in Patients with Liver Cirrhosis, A Three-Dimensional Printable Hydrogel Formulation for the Local Delivery of Therapeutic Nanoparticles to Cervical Cancer, Curcumin Transferosome-Loaded Thermosensitive Intranasal In Situ Gel as Prospective Antiviral Therapy for SARS-CoV-2, and Externally Triggered Novel Rapid-Release Sonosensitive Folate-Modified Liposomes for Gemcitabine. Additional studies such as RNAi Screening of Drosophila S2 Cells for Ricin Sensitivity and Resistance, High-Sensitivity Permeation Analysis of Ultrasmall Nanoparticles Across the Skin by Positron Emission Tomography, Unique PDC Bit Design Significantly Improves Drilling Efficiency Across Several Interbedded Formations, and A Diffusion Cell Adapted to Nuclear Imaging Instruments for the Measurement of Molecular Release and Pharmacokinetics Across Membranes highlight his interdisciplinary expertise. Prof. Dr. Omar’s pioneering work continues to influence the fields of drug delivery, biomedical engineering, and nanopharmaceutical development globally.

Profile: Google Scholar

Featured Publications

  • Eleraky, N. E., Allam, A., Hassan, S. B., & Omar, M. M. (2020). Nanomedicine fight against antibacterial resistance: An overview of the recent pharmaceutical innovations. Pharmaceutics, 12(2), 1–49.

  • Omar, M. M., Hasan, O. A., & El Sisi, A. M. (2019). Preparation and optimization of lidocaine transferosomal gel containing permeation enhancers: A promising approach for enhancement of skin permeation. International Journal of Nanomedicine, 14, 1551–1562.

  • Omar, M. M., Abdel-Rashid, R. S., Helal, D. A., & El Sisi, A. M. (2019). Nanogel loaded with surfactant-based nanovesicles for enhanced ocular delivery of acetazolamide. International Journal of Nanomedicine, 14, 2973–2983.

  • Eleraky, N. E., Omar, M. M., Mahmoud, H. A., & Abou-Taleb, H. A. (2020). Nanostructured lipid carriers to mediate brain delivery of temazepam: Design and in vivo study. Pharmaceutics, 12(5), 451.

  • Salem, H. F., Ahmed, S. M., & Omar, M. M. (2016). Liposomal flucytosine capped with gold nanoparticles formulations for improved ocular delivery. Drug Design, Development and Therapy, 10, 277–295.

 

Yi Yao | Nanomedicine | Best Researcher Award

Published on by Global Nano Awards

Prof. Yi Yao | Nanomedicine | Best Researcher Award

Renmin Hospital of Wuhan University | China

Prof. Yi Yao is a distinguished oncologist, Ph.D., Chief Physician, and Director of the Cancer Center at Renmin Hospital of Wuhan University, China, with a career dedicated to advancing cancer treatment and research. He earned his medical degree and doctorate from Wuhan University and received international training as a Visiting Scholar at the German Cancer Research Center, Heidelberg University, and MD Anderson Cancer Center in the United States. His clinical and research interests focus on tumor radiotherapy and the tumor immune microenvironment, with particular emphasis on how irradiation influences tumor biology, radiotherapy efficacy, and radiation-induced lung injury, including the role of fibroblasts and tumor interstitial fibrosis in treatment outcomes. Prof. Yao has secured major research funding from the National Natural Science Foundation of China, the Hubei Natural Science Foundation, and multiple institutional projects, while building collaborations with world-leading cancer research centers in Germany and the United States. He has published extensively in high-impact journals such as Nature Communications, The EMBO Journal, Journal of Clinical Oncology, Cancer Medicine, Histopathology, Nano Letters, and Frontiers in Immunology, in addition to co-editing oncology volumes and holding software copyrights. Recognized with numerous national, provincial, and institutional awards for his contributions to research, clinical practice, and mentorship, Prof. Yao serves on national and provincial oncology committees, is a member of ASCO and ESMO, and continues to mentor doctoral and master’s students, making lasting contributions to oncology education, clinical innovation, and cancer research.

Profile: Orcid

Featured publications

  • Zhang, H., Chen, L., Li, L., Liu, Y., Das, B., Zhai, S., Tan, J., Jiang, Y., Turco, S., Yao, Y., & Frishman, D. (2025). Prediction and analysis of tumor infiltrating lymphocytes across 28 cancers by TILScout using deep learning. NPJ Precision Oncology, 9(1), 76.

  • Dong, Y., Khan, L., & Yao, Y. (2024). Immunological features of EGFR-mutant NSCLC and clinical practice. Journal of the National Cancer Center, 4(4), 289–298.

  • Yi, L., Wen, Y., Xiao, M., Yuan, J., Ke, X., Zhang, X., Khan, L., Song, Q., & Yao, Y. (2024). The proportion of tumour stroma predicts response to immune checkpoint inhibitor plus chemotherapy in stage IIIB–IV NSCLC. Histopathology, 85(2), 295–309.

  • Yao, Y., Shen, Y., Yao, J. C., & Zuo, X. (2024). Editorial: New advancement in tumor microenvironment remodeling and cancer therapy. Frontiers in Cell and Developmental Biology, 12, 1384567.

  • Li, Y., Chen, J., Wang, B., Xu, Z., Wu, C., Ma, J., Song, Q., Geng, Q., Yu, J., Pei, H., & Yao, Y. (2023). FOXK2 affects cancer cell response to chemotherapy by promoting nucleotide de novo synthesis. Drug Resistance Updates, 67, 100926.

  • Yao, Y., Chu, Y., & Xu, B. (2019). Radiotherapy after surgery has significant survival benefits for patients with triple-negative breast cancer. Cancer Medicine, 8(2), 554–563.